GlobeStar Therapeutics (GSTC) Stock Statistics & Valuation Metrics
Total Valuation
GlobeStar Therapeutics has a market cap or net worth of $1,241.00. The enterprise value is $490.12B.
- Market Cap
- $1,241.00
- Enterprise Value
- $490.12B
Share Statistics
GlobeStar Therapeutics has 1,241,105,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,241,105,700
- Owned by Insiders
- ―
- Owned by Institutions
- <0.01%
Financial Efficiency
GlobeStar Therapeutics’s return on equity (ROE) is 1.36 and return on invested capital (ROIC) is 174.56%.
- Return on Equity (ROE)
- 1.36
- Return on Assets (ROA)
- 0.00
- Return on Invested Capital (ROIC)
- 174.56%
- Return on Capital Employed (ROCE)
- 1.30
- Revenue Per Employee
- ―
- Profits Per Employee
- ―
- Employee Count
- 0
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of GlobeStar Therapeutics is -0.04. GlobeStar Therapeutics’s PEG ratio is -0.00.
- PE Ratio
- -0.04
- PS Ratio
- 0.00
- PB Ratio
- -0.06
- Price to FCF
- -0.60
- Price to Operating Cash Flow
- -0.40
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, GlobeStar Therapeutics had revenue of 0 and earned -1.95M in profits. Earnings per share was -0.00.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -1.86M
- Pretax Income
- -1.95M
- Net Income
- -1.95M
- EBITDA
- 6,370
- Earnings Per Share (EPS)
- -0.00
Cash Flow
In the last 12 months, operating cash flow was -148.28K and capital expenditures 4, giving a free cash flow of -148.28K billion.
- Operating Cash Flow
- -148.28K
- Free Cash Flow
- -148.28K
- Free Cash Flow per Share
- -0.00
Dividends & Yields
GlobeStar Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -165.79%
- Earnings Yield
- -2355.79%
Stock Price Statistics
- Beta
- 15.83
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Financial Position
GlobeStar Therapeutics as a current ratio of 0.00, with Debt / Equity ratio of -25.53%
- Current Ratio
- 0.00
- Quick Ratio
- 0.00
- Debt to Market Cap
- 0.25
- Net Debt to EBITDA
- 54.43
- Interest Coverage Ratio
- -20.35
Taxes
In the past 12 months, GlobeStar Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
GlobeStar Therapeutics EV to EBITDA ratio is 76.94, with an EV/FCF ratio of -2.38.
- EV to Sales
- 0.00
- EV to EBITDA
- 76.94
- EV to Free Cash Flow
- -2.38
- EV to Operating Cash Flow
- -2.38
Balance Sheet
GlobeStar Therapeutics has $41.00 in cash and marketable securities with $329.05K in debt, giving a net cash position of -$329.01K billion.
- Cash & Marketable Securities
- $41.00
- Total Debt
- $329.05K
- Net Cash
- -$329.01K
- Net Cash Per Share
- $0.00
- Tangible Book Value Per Share
- $0.00
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for GlobeStar Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
